{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:39:28Z","timestamp":1793950768383,"version":"4.8.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019533","name":"Moderna","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.omtn.2023.102043","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T01:11:53Z","timestamp":1696468313000},"page":"102043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Induction of long-term tolerance to a specific antigen using anti-CD3 lipid nanoparticles following gene therapy"],"prefix":"10.1016","volume":"34","author":[{"given":"Chun-Yu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Vander Kooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Cavedon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohe","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Hoggatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo G.V.","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6520-2373","authenticated-orcid":false,"given":"Carol H.","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2023.102043_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12016-009-8119-0","article-title":"Characteristics, mechanisms of action, and epitope mapping of anti-factor VIII antibodies","volume":"37","author":"Lavigne-Lissalde","year":"2009","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.omtn.2023.102043_bib2","doi-asserted-by":"crossref","first-page":"498","DOI":"10.4049\/immunohorizons.1900019","article-title":"Homotaurine Treatment Enhances CD4(+) and CD8(+) Regulatory T Cell Responses and Synergizes with Low-Dose Anti-CD3 to Enhance Diabetes Remission in Type 1 Diabetic Mice","volume":"3","author":"Tian","year":"2019","journal-title":"Immunohorizons"},{"key":"10.1016\/j.omtn.2023.102043_bib3","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/intimm\/13.9.1109","article-title":"Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on T(h)1 cells that is augmented by IL-4","volume":"13","author":"Tran","year":"2001","journal-title":"Int. Immunol."},{"key":"10.1016\/j.omtn.2023.102043_bib4","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.4049\/jimmunol.153.7.3319","article-title":"Induction of T helper cell hyporesponsiveness in an experimental model of autoimmunity by using nonmitogenic anti-CD3 monoclonal antibody","volume":"153","author":"Hughes","year":"1994","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtn.2023.102043_bib5","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.4049\/jimmunol.174.8.4525","article-title":"Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T\u00a0cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis","volume":"174","author":"Kohm","year":"2005","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtn.2023.102043_bib6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2023.102043_bib7","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/dmrr.933","article-title":"Anti-CD3 mAbs for treatment of type 1 diabetes","volume":"25","author":"Kaufman","year":"2009","journal-title":"Diabetes. Metab. Res. Rev."},{"key":"10.1016\/j.omtn.2023.102043_bib8","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00125-018-4786-9","article-title":"Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis","volume":"62","author":"Perdigoto","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.omtn.2023.102043_bib9","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/ibd.21084","article-title":"Prospective randomized open-label multicenter phase I\/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis","volume":"16","author":"Baumgart","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.omtn.2023.102043_bib10","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1097\/00007890-199912150-00005","article-title":"Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection","volume":"68","author":"Friend","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.omtn.2023.102043_bib11","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1182\/blood.V99.8.2712","article-title":"A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease","volume":"99","author":"Carpenter","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2023.102043_bib12","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/00007890-199909150-00003","article-title":"Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection","volume":"68","author":"Woodle","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.omtn.2023.102043_bib13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1189\/jlb.1112584","article-title":"Characteristics of TCR\/CD3 complex CD3{varepsilon} chains of regulatory CD4+ T (Treg) lymphocytes: role in Treg differentiation in\u00a0vitro and impact on Treg in\u00a0vivo","volume":"95","author":"Rojo","year":"2014","journal-title":"J.\u00a0Leukoc. Biol."},{"key":"10.1016\/j.omtn.2023.102043_bib14","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.4049\/jimmunol.1401551","article-title":"Heterogeneous CD3 expression levels in differing T\u00a0cell subsets correlate with the in\u00a0vivo anti-CD3-mediated T\u00a0cell modulation","volume":"194","author":"Valle","year":"2015","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtn.2023.102043_bib15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12967-019-1804-8","article-title":"How mRNA therapeutics are entering the monoclonal antibody field","volume":"17","author":"Van Hoecke","year":"2019","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.omtn.2023.102043_bib16","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.15252\/emmm.201707678","article-title":"mRNA mediates passive vaccination against infectious agents, toxins, and tumors","volume":"9","author":"Thran","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtn.2023.102043_bib17","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nm.4356","article-title":"Elimination of large tumors in mice by mRNA-encoded bispecific antibodies","volume":"23","author":"Stadler","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2023.102043_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14630","article-title":"Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge","volume":"8","author":"Pardi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2023.102043_bib19","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1021\/acs.nanolett.7b02664","article-title":"Boosting Intracellular Delivery of Lipid Nanoparticle-Encapsulated mRNA","volume":"17","author":"Patel","year":"2017","journal-title":"Nano Lett."},{"key":"10.1016\/j.omtn.2023.102043_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/0300985817738095","article-title":"Safety Evaluation of Lipid Nanoparticle-Formulated Modified mRNA in the Sprague-Dawley Rat and Cynomolgus Monkey","volume":"55","author":"Sedic","year":"2018","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.omtn.2023.102043_bib21","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.omtn.2020.03.015","article-title":"Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles","volume":"20","author":"Chen","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2023.102043_bib22","doi-asserted-by":"crossref","first-page":"923","DOI":"10.4049\/jimmunol.172.2.923","article-title":"Alloantigen-induced CD25+CD4+ regulatory T\u00a0cells can develop in\u00a0vivo from CD25-CD4+ precursors in a thymus-independent process","volume":"172","author":"Karim","year":"2004","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtn.2023.102043_bib23","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.intimp.2015.03.049","article-title":"Induction of antigen specific CD4(+)CD25(+)Foxp3(+)T regulatory cells from naive natural thymic derived T regulatory cells","volume":"28","author":"Hall","year":"2015","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.omtn.2023.102043_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-7312-5_1","article-title":"Platforms for Recombinant Therapeutic Glycoprotein Production","volume":"1674","author":"Mizukami","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omtn.2023.102043_bib25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fimmu.2013.00217","article-title":"Expression of recombinant antibodies","volume":"4","author":"Frenzel","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2023.102043_bib26","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/glycob\/cwv065","article-title":"Fc glycans of therapeutic antibodies as critical quality attributes","volume":"25","author":"Reusch","year":"2015","journal-title":"Glycobiology"},{"key":"10.1016\/j.omtn.2023.102043_bib27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0014-5793(90)81427-P","article-title":"Sialylated carbohydrate chains of recombinant human glycoproteins expressed in Chinese hamster ovary cells contain traces of N-glycolylneuraminic acid","volume":"275","author":"Hokke","year":"1990","journal-title":"FEBS Lett."},{"key":"10.1016\/j.omtn.2023.102043_bib28","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1159\/000188946","article-title":"Failure of human immunoresponse to N-glycolylneuraminic acid epitope contained in recombinant human erythropoietin","volume":"72","author":"Noguchi","year":"1996","journal-title":"Nephron"},{"key":"10.1016\/j.omtn.2023.102043_bib29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1472-6750-13-52","article-title":"High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells","volume":"13","author":"J\u00e4ger","year":"2013","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.omtn.2023.102043_bib30","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/19420862.2019.1598230","article-title":"An anti-apoptotic HEK293 cell line provides a robust and high titer platform for transient protein expression in bioreactors","volume":"11","author":"Arena","year":"2019","journal-title":"mAbs"},{"key":"10.1016\/j.omtn.2023.102043_bib31","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jbiotec.2017.04.028","article-title":"Therapeutic glycoprotein production in mammalian cells","volume":"251","author":"Lalonde","year":"2017","journal-title":"J.\u00a0Biotechnol."},{"key":"10.1016\/j.omtn.2023.102043_bib32","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/biot.201400052","article-title":"Avoiding antibody aggregation during processing: establishing hold times","volume":"9","author":"Joshi","year":"2014","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.omtn.2023.102043_bib33","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41587-020-0507-2","article-title":"Viral contamination in biologic manufacture and implications for emerging therapies","volume":"38","author":"Barone","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2023.102043_bib34","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1101\/gad.319475.118","article-title":"RNA m(6) A modification enzymes shape innate responses to DNA by regulating interferon beta","volume":"32","author":"Rubio","year":"2018","journal-title":"Genes Dev."},{"key":"10.1016\/j.omtn.2023.102043_bib35","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.biomaterials.2017.11.034","article-title":"Emergence of synthetic mRNA: In\u00a0vitro synthesis of mRNA and its applications in regenerative medicine","volume":"156","author":"Kwon","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.omtn.2023.102043_bib36","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.omtn.2018.06.010","article-title":"Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification","volume":"12","author":"Vaidyanathan","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2023.102043_bib37","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1038\/s41598-020-64017-0","article-title":"Systemic modified messenger RNA for replacement therapy in alpha 1-antitrypsin deficiency","volume":"10","author":"Karadagi","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2023.102043_bib38","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1111\/bph.15040","article-title":"Disease pharmacokinetic-pharmacodynamic modelling in acute intermittent porphyria to support the development of mRNA-based therapies","volume":"177","author":"Parra-Guillen","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.omtn.2023.102043_bib39","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2023.102043_bib40","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2023.102043_bib41","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1016\/j.vaccine.2020.06.062","article-title":"Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates","volume":"38","author":"Monslow","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.omtn.2023.102043_bib42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41541-020-0163-z","article-title":"Modified mRNA\/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection","volume":"5","author":"Espeseth","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.omtn.2023.102043_bib43","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/infdis\/jiz338","article-title":"Protective Efficacy of Nucleic Acid Vaccines Against Transmission of Zika Virus During Pregnancy in Mice","volume":"220","author":"Jagger","year":"2019","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.omtn.2023.102043_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw6647","article-title":"A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection","volume":"4","author":"Kose","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.omtn.2023.102043_bib45","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.celrep.2017.11.081","article-title":"Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia","volume":"21","author":"An","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2023.102043_bib46","doi-asserted-by":"crossref","first-page":"e006628","DOI":"10.1136\/jitc-2022-006628","article-title":"Vaccinating against cancer: getting to prime time","volume":"11","author":"Chang","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omtn.2023.102043_bib47","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1089\/nat.2022.0036","article-title":"Translational Pharmacokinetic\/Pharmacodynamic Model for mRNA-3927, an Investigational Therapeutic for the Treatment of Propionic Acidemia","volume":"33","author":"Attarwala","year":"2023","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2023.102043_bib48","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41541-023-00656-4","article-title":"An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection","volume":"8","author":"Bollman","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.omtn.2023.102043_bib49","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(22)00764-2","article-title":"The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials","volume":"23","author":"Essink","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.omtn.2023.102043_bib50","article-title":"Human cytomegalovirus mRNA-1647 vaccine candidate elicits potent and broad neutralization and higher antibody-dependent cellular cytotoxicity responses than that of the partially effective gB\/MF59 vaccine","author":"Hu","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.omtn.2023.102043_bib51","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cytogfr.2022.10.001","article-title":"Development of mRNA vaccines against respiratory syncytial virus (RSV)","volume":"68","author":"Qiu","year":"2022","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.omtn.2023.102043_bib52","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2019.1703531","article-title":"Antibodies to watch in 2020","volume":"12","author":"Kaplon","year":"2020","journal-title":"mAbs"},{"key":"10.1016\/j.omtn.2023.102043_bib53","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00125-020-05317-y","article-title":"A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes","volume":"64","author":"Keymeulen","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.omtn.2023.102043_bib54","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41422-022-00630-0","article-title":"Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters","volume":"32","author":"Deng","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.omtn.2023.102043_bib55","article-title":"Lipid Nanoparticle Delivery System for mRNA Encoding B7H3-redirected Bispecific Antibody Displays Potent Antitumor Effects on Malignant Tumors","volume":"10","author":"Huang","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.omtn.2023.102043_bib56","first-page":"558","article-title":"Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors","volume":"91","author":"Rocino","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.omtn.2023.102043_bib57","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1046\/j.1365-2516.2000.00436.x","article-title":"The Malmo model for immune tolerance induction: impact of previous treatment on outcome","volume":"6","author":"Carlborg","year":"2000","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"10.1016\/j.omtn.2023.102043_bib58","first-page":"49","article-title":"Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome","volume":"77","author":"Oldenburg","year":"1999","journal-title":"Vox Sang."},{"key":"10.1016\/j.omtn.2023.102043_bib59","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.blre.2018.02.003","article-title":"Review of immune tolerance induction in hemophilia A","volume":"32","author":"Schep","year":"2018","journal-title":"Blood Rev."},{"key":"10.1016\/j.omtn.2023.102043_bib60","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.clim.2009.06.001","article-title":"First-in-man clinical results of the treatment of patients with graft versus host disease with human ex\u00a0vivo expanded CD4+CD25+CD127- T regulatory cells","volume":"133","author":"Trzonkowski","year":"2009","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.omtn.2023.102043_bib61","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2010-07-293795","article-title":"Infusion of ex\u00a0vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics","volume":"117","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2023.102043_bib62","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jcyt.2014.11.005","article-title":"Adoptive transfer of allogeneic regulatory T\u00a0cells into patients with chronic graft-versus-host disease","volume":"17","author":"Theil","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omtn.2023.102043_bib63","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1182\/blood-2010-10-311894","article-title":"Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation","volume":"117","author":"Di Ianni","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2023.102043_bib64","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/ajt.14175","article-title":"Prevention of Allograft Rejection by Use of Regulatory T Cells With an MHC-Specific Chimeric Antigen Receptor","volume":"17","author":"Noyan","year":"2017","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.omtn.2023.102043_bib65","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/ajt.14185","article-title":"Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection","volume":"17","author":"Boardman","year":"2017","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.omtn.2023.102043_bib66","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3389\/fimmu.2020.00638","article-title":"A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy","volume":"11","author":"Chen","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2023.102043_bib67","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/mt.2011.61","article-title":"In\u00a0vivo expansion of regulatory T\u00a0cells with IL-2\/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy","volume":"19","author":"Liu","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2023.102043_bib68","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1182\/blood-2009-05-217315","article-title":"Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy","volume":"114","author":"Peng","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2023.102043_bib69","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/cvr\/cvu002","article-title":"Regression of atherosclerosis with anti-CD3 antibody via augmenting a regulatory T-cell response in mice","volume":"102","author":"Kita","year":"2014","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.omtn.2023.102043_bib70","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1182\/blood-2008-04-151597","article-title":"Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response","volume":"113","author":"Waters","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2023.102043_bib71","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.4049\/jimmunol.158.6.2947","article-title":"CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice","volume":"158","author":"Chatenoud","year":"1997","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtn.2023.102043_bib72","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ymthe.2019.03.002","article-title":"mRNA: A Novel Avenue to Antibody Therapy?","volume":"27","author":"Schlake","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2023.102043_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2023.104675","article-title":"Suppression of anti-drug antibody formation against coagulation factor VIII by oral delivery of anti-CD3 monoclonal antibody in hemophilia A mice","volume":"385","author":"Bertolini","year":"2023","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.omtn.2023.102043_bib74","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2023.102043_bib75","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/jth.12576","article-title":"Long-term tolerance to factor VIII is achieved by administration of interleukin-2\/interleukin-2 monoclonal antibody complexes and low dosages of factor VIII","volume":"12","author":"Liu","year":"2014","journal-title":"J.\u00a0Thromb. Haemostasis"},{"key":"10.1016\/j.omtn.2023.102043_bib76","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1182\/blood-2008-01-128413","article-title":"Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice","volume":"112","author":"Peng","year":"2008","journal-title":"Blood"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253123002615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253123002615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T01:53:47Z","timestamp":1744509227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253123002615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":76,"alternative-id":["S2162253123002615"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2023.102043","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Induction of long-term tolerance to a specific antigen using anti-CD3 lipid nanoparticles following gene therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2023.102043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023","name":"copyright","label":"Copyright"}],"article-number":"102043"}}